An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist
Diamond LE, Earle DC, Heiman JR, et al. Journal of Sexual Medicine 2006;3:628-638.
What it found
More women reported moderate or high sexual desire after bremelanotide than after placebo. Among women who attempted intercourse within 24 hours, more were satisfied with their arousal after bremelanotide. Measured vaginal blood flow during erotic videos did not change.
Limitations
Only 18 women, single dose, crossover design. Several outcomes were trends rather than clear differences. Run by the developer.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.